William Blair analyst Matt Phipps has reiterated their bullish stance on NAMS stock, giving a Buy rating on June 4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Matt Phipps has given his Buy rating due to a combination of factors that highlight NewAmsterdam Pharma Company’s potential for growth and innovation. The company recently announced promising results from a sub-study of their Phase III BROADWAY trial, which showed positive Alzheimer’s disease biomarker data. This development, although not yet included in current financial assumptions, suggests a significant long-term upside if the Alzheimer’s benefits are realized.
Additionally, the competitive landscape is favorable for NewAmsterdam, especially with the differentiation of their product, obicetrapib, which could offer a unique profile in the market. The potential for LDL cholesterol reduction below 55% through a fixed-dose combination with ezetimibe further strengthens their position. These factors, combined with the anticipation of more detailed insights at their upcoming R&D day, underpin Phipps’s optimistic outlook on the company’s stock.
In another report released on June 4, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $42.00 price target.